Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics Inc (NQ: IOVA )

7.980 -0.150 (-1.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,664,697
Open 7.950
Bid (Size) 7.950 (3)
Ask (Size) 8.000 (1)
Prev. Close 8.130
Today's Range 7.910 - 8.150
52wk Range 5.420 - 18.73
Shares Outstanding 157,840,581
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
 
Via Benzinga
American Express, Visa And Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga

Performance

YTD
+30.61%
+30.61%
1 Month
+25.87%
+25.87%
3 Month
-2.80%
-2.80%
6 Month
-35.17%
-35.17%
1 Year
-49.72%
-49.72%

More News

Read More
The Latest Analyst Ratings for Iovance Biotherapeutics
Via Benzinga
What 6 Analyst Ratings Have To Say About Iovance Biotherapeutics
Via Benzinga
What 4 Analyst Ratings Have To Say About Iovance Biotherapeutics
Via Benzinga
Why Iovance Biotherapeutics Stock Soared 12% Higher Today
Via The Motley Fool
Iovance Biotherapeutics Acquires Clinigen's IL-2 Product For Upfront £166.7M
Via Benzinga
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Why Is Iovance Biotherapeutics (IOVA) Stock Soaring 20% Today?
Via InvestorPlace
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
US Stocks Start Week On Lower Note; Dow Tumbles 250 Points
Via Benzinga
Iovance Biotherapeutics Stock Is Surging: Here's Why
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
$65 Million Bet On Iovance Biotherapeutics? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
NIO To Surge Around 105%? Plus Keybanc Predicts $165 For This Stock
Via Benzinga
Why Iovance Biotherapeutics Is Crashing Today
Via The Motley Fool
Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.